Many of New Jersey’s innovative biopharma companies advanced recently on their way to new FDA drug approvals, including BioNJ Members Scynexis, Soligenix and Eli Lilly & Co., giving fresh hope to Patients and their families around the world. Because Patients Can’t WaitSM, BioNJ is excited for our fall lineup of events — bringing together the Garden State’s life sciences community for meaningful discussions on how to bring new therapies and cures to the Patients who need them.
Whether you plan to take your product all the way to market or not, BioNJ’s 4th Annual CEO Summit, taking place September 23, examines the critical factors that need to be considered along your journey. Whether large or small, public or private, pre-revenue or not…this robust agenda addresses the challenges that the C-Suite faces day in day out — from fundraising to financing…politics to pricing. Click here to register.
Featuring a schedule of interactive sessions, BioNJ’s inaugural Patient Advocacy Summit will bring together patients, patient advocacy groups, industry and government for a day of Education, Engagement and Empowerment. Registration is open to patient advocacy groups and patient advocacy professionals in BioNJ Member companies. Click here if you are interested in attending.
Taking place on December 8, Beyond Value Frameworks: Measuring Health Benefits from a Patient’s Point of View is an invitation-only program for individuals responsible for pricing, policy, market access and reimbursement within BioNJ Innovation Member companies. Workshop participants will learn how to get ahead of framework decisions, develop partnerships to challenge value assessments, discuss ways to measure patient-centered value and learn about new analytic computational platforms that can demonstrate and calculate drug value.
It’s an exciting time for New Jersey as global biopharmaceutical leaders Allergan and Mallinckrodt announced their respective commitments to the Garden State — confirming what we already knew — New Jersey is home to first-rate talent, a thriving biopharma industry, business friendly resources, world-class institutions and unstoppable innovation. Go New Jersey!
Click here to read this week’s Weekender.